Trivitron Healthcare has entered into a strategic partnership with Diasorin Group to enter the immunodiagnostic market in India. The DiaSorin- Trivitron partnership has formed the capital companies DiaSorin Trivitron Healthcare Private Limited, in which the parties will have 51 per cent and 49 per cent stakes respectively. The company will directly operate in the Indian diagnostics market.
Dr GSK Velu, Founder and MD, Trivitron Group of Companies said, “The joint venture with Diasorin is an important milestone for Trivitron to achieve market leadership position in the Indian IVD segment. We are confident that the venture will provide unique positioning for Trivitron. Trivitron has always excelled in building market leadership position in immunoassay segment with the most innovative and extensive Immunoassay platform using CLIA/ ELISA/ RIA/MDx. Combining the strengths of Diasorin and Trivitron, in the next three years we attempt to reach leadership position in Indian immunoassay segment.”
Trivitron has been a contributor in this segment wherein the company installed immunoassay analyzers in almost 70 per cent of labs in India. It is the first company to launch the Chemi Luminescence Immuno Assay (CLIA) platform in India.
Carlo Rosa, CEO of DiaSorin Group, commented that the JV agreement with Trivitron is really important for the success of DiaSorin Group in such relevant market as India, and represents an important pillar of the current and future expansion strategy of DiaSorin Group in Asia Pacific.
- Advertisement -
